Clinical Trials | March 23, 2023
Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
This is especially the case if the patients are young, have multiple blocks & have conditions that may make angioplasty to implant drug-eluting stents ineffective
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Amala Hospital partners with LifeSigns to provide revolutionary technology for the first time in the State
Twelve hospitals across India will be part of the network which will support the trial in India
Subscribe To Our Newsletter & Stay Updated
